Oops Natco Pharma launches epilepsy treatment drug Brivaracetam in India - GrowMudra

Top companies

ASIANPAINT - 2268.5 (0.42%) AXISBANK - 1193 (0.07%) BAJAJFINSV - 2026.2 (0.44%) BAJFINANCE - 9119 (-0.67%) BHARTIARTL - 1850 (-0.33%) BPCL - 316.6 (-0.57%) COALINDIA - 399.2 (0.48%) HDFCBANK - 1931 (-0.71%) HEROMOTOCO - 4221 (-2.05%) HINDUNILVR - 2367.9 (0.83%) ICICIBANK - 1447.7 (0.13%) INDUSINDBK - 812.05 (-0.6%) ITC - 418.5 (0.11%) KOTAKBANK - 2061.2 (-0.65%) MARUTI - 12273 (-0.37%) ONGC - 238.04 (-0.57%) RELIANCE - 1412.6 (-0.58%) SBIN - 813.5 (0.15%) TATAMOTORS - 711.55 (-1.1%) TATASTEEL - 159.12 (-1.18%) TCS - 3445.8 (-0.51%) TITAN - 3534.9 (-0.57%) WIPRO - 247.58 (-0.84%)
TRENDING #Nifty 502 #REC Limited1 #Nifty Bank1 #Yes Bank1

Natco Pharma launches epilepsy treatment drug Brivaracetam in India

26 Feb , 2021   By : kanchan Joshi


Natco Pharma launches epilepsy treatment drug Brivaracetam in India

Natco Pharma NSE 1.13 % on Friday said it has launched epilepsy treatment drug 'Brivaracetam' in the country.

The company has launched Brivaracetam tablets under brand BRECITA in India, Natco Pharma said in a regulatory filing.


Brivaracetam, indicated towards the treatment of epilepsy, is developed by UCB Pharma and currently marketed in India by Dr Reddy's under the brand name Briviact.


Natco Pharma said epilepsy patients in India are estimated to be between 5-10 million, as per GEMIND guidelines.


Natco has launched BRECITA tablets in strengths of 50 mg and 100 mg priced at Rs 25 and Rs 35 per tablet, respectively.



0 Comment


LEAVE A COMMENT


Growmudra © 2025 all right reserved

Partner With Us